Checkpoint Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of cash flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Cash Flows from Operating Activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
Issuance of common shares - Founders Agreement
Common shares issuable - Founders Agreement
Loss on common stock warrant liabilities
Loss (gain) on common stock warrant liabilities
Changes in operating assets and liabilities:
Prepaid expenses and other assets
Other receivables - related party
Accounts payable and accrued expenses
Accounts payable and accrued expenses - related party
Net cash used in operating activities
Cash Flows from Financing Activities:
Proceeds from issuance of common stock - Public offering
Offering costs for the issuance of common stock - Public offering
Proceeds from issuance of common stock - At-the-market offering
Offering costs for the issuance of common stock - At-the-market offering
Issuance of common shares - Registered direct offerings
Direct offering
At the market offering (ATM)
Total issuance of common shares - Registered direct offerings
Payment of offering costs for the issuance of common shares - Registered direct offerings
Direct offering
At the market offering (ATM)
Total payment of offering costs for the issuance of common shares - Registered direct offerings
Net settlement of shares withheld for payment of employee taxes
Payment of Fractional shares
Cash received for exercise of warrants
Payment of transactional costs for exercise of warrants
Net cash provided by financing activities

Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure of noncash investing and financing activities:
Issuance of common shares - Founders Agreement
Issuance of common shares - Public offering (offering costs incurred but not paid)
Issuance of common shares - Registered direct offerings (offering costs incurred but not paid)
Warrant inducement (transactional costs incurred but not paid)

Comments